CLOSTRIDIUM DIFFICILE DIAGNOSTICS MARKET ANALYSIS

Clostridium difficile is a causative agent for various gut disorders with symptoms such as diarrhea, nausea, colon inflammation, and others. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of C. difficile bacteria. Common symptoms of clostridium difficile infection include watery diarrhea, dehydration, fever, nausea, loss of appetite, and weight loss. Life threatening symptoms of the disease includes abdominal distension, severe abdominal pain, and profuse diarrhea. Clostridium difficile infection management includes diagnosis of the infection using various tests and medication therapies using antibiotics such as Vancomycin and Fidaxomicin.

Global clostridium difficile diagnostics market is estimated to be valued at US$ 838.05 million in 2022 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2022-2030).

Figure 1.Global Clostridium Difficile Diagnostics Market Share (%), by Diagnostic Test, 2022

To learn more about this report, request sample copy

Global Clostridium Difficile Diagnostics Market- Drivers

The increasing prevalence of clostridium difficile infection (CDI) is anticipated to boost the demand for its diagnosis, which is expected to drive the global clostridium difficile diagnostics market growth. For instance, according to the data published by Cureus, an open access medical journal, in December 2021, C. difficile infection (CDI) impacts 13 in every 1,000 patients globally and about 75% of cases are considered hospital-acquired. Higher rates of hospital admissions and antibiotic use have been linked with increased rates of healthcare-associated CDI (HA-CDI). Nosocomial CDI is linked to increased morbidity and mortality.

Moreover, increasing approval of diagnostics tests/assays by regulatory authorities is expected to drive the market growth over the forecast period. For instance, in November 2018, Singulex, Inc., an immunodiagnostics company, announced the commercial introduction of its Clarity C. difftoxin A/B assay, a rapid, high-sensitivity, high-precision, for C. difficile toxin testing. The assay matches the sensitivity and specificity of cell cytotoxicity neutralization assays, giving it the potential to reduce the false positives of polymerase chain reaction-based tests and the false negatives of current, less-sensitive toxin immunoassays.

Figure 2.Global Clostridium Difficile Diagnostics Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Global Clostridium Difficile Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. COVID-19 had limited impact on the global clostridium difficile diagnostics market. For instance, according to an article published by Elsevier Inc., in August 2022, during the COVID-19 pandemic, several factors, such as improved hand hygiene, social distancing, and restricted hospital referral, may have had an influence on the epidemiology of Clostridioides difficile infections (CDI).  

Global Clostridium Difficile Diagnostics Market: Key Developments

In 2021, the two German companies, Novatec Immundiagnostica GmbH and Virotech Diagnostics GmbH, collaborated to form Gold Standard Diagnostics Europe. The newly formed company is focusing on both human and veterinary markets, as it is manufacturing diagnostic kits for infectious diseases (bacterial, viral, and parasitic diseases), hormones, and autoimmunity.

Global Clostridium Difficile Diagnostics Market: Restraint

Low awareness about clostridium difficile infection symptoms and associated effects is expected to restrain the growth of the clostridium difficile diagnostics market over the forecast period.

For instance, according to an article published by Cambridge University, in 2017, titled ‘Prevalence of Clostridium difficile infection and colonization in a tertiary hospital and elderly community of North-Eastern Peninsular Malaysia’, an awareness survey population was conducted amongst University hospital staff (i.e. doctors, non-clinical medical professionals, and paramedics) and students (i.e. undergraduates and postgraduates) who were involved with in-hospital patient care, which comprised of five multiple-choice questions.

Global Clostridium Difficile Diagnostics Market- Key Players

Major players operating in the global clostridium difficile diagnostics market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Inc., Abbott Laboratories, Trinity Biotech Plc., Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc